GlassScriptPhysician profile
Michael Mosquera
NPI 1487460952
$700.42
in general payments reported to CMS, 2019-2025
16 companies · $654 in 2025
The $654 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $46.37 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $81.74 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $81.27 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.34 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $62.24 | 2025 | Austedo Xr |
| Biogen, INC. | $61.30 | 2025 | Zurzuvae |
| Astrazeneca Pharmaceuticals LP | $59.19 | 2025 | Breztri, Airsupra |
| Novo Nordisk INC | $54.08 | 2025 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $47.62 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $46.37 | 2024 | |
| Sanofi Pasteur INC. | $26.27 | 2025 | |
| Abbvie INC. | $21.86 | 2025 | |
| Pfizer INC. | $21.44 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.46 | 2025 | Caplyta |
| Cipher Pharmaceuticals US LLC | $16.08 | 2025 | Spinosad, Natroba |
| Viiv Healthcare Company | $15.72 | 2025 | Apretude |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.44 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mosquera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.